Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Company Logo

Destroying Cancer at the Speed of Light®

Clinical Study Underway (75 of 100 Patients Treated)
Expected to complete enrollment at the end of 2024
Expected to complete study at the end of 2026


Bullboard - Investor Discussion Forum Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

TSXV:TLT - Post Discussion

View:
Post by N0taP00p on Jul 05, 2024 1:37pm

End of Q3

Some of us mentioned the fact that if there's a saviour who's willing to buy a large chunk of whatever PP was floated, we should have known by last week.  No need to speculate anymore?  At this point, it seems likely that the flurry of NRs was to try and amp up interest. So much for that. At this point, our only hope is that they don't push BTD again.  If it pushes to Q4, some will still say "imminent". I'll finally be selling most of my shares,  after waiting more than a dozen years, and extending my sell timeline by one year. From the RIGHT side of my brain,  Godspeed to the TLT team to get this over the FDA hump in Q3.
Comment by Oilminerdeluxe on Jul 05, 2024 2:13pm
Isn't BTD, if it comes, scheduled for Q4 already?
Comment by N0taP00p on Jul 05, 2024 2:35pm
@Oilminer: I guess we'll need to hear some official version of that. I don't remember seeing anything.  I'd feel encouraged if they said they resubmitted the pre-BTD application with full validation completed by the central lab + 450 day data. 
Comment by Oilminerdeluxe on Jul 05, 2024 3:03pm
I think someone did some math and concluded October. But I might remember it wrong. 
Comment by plantrader on Jul 05, 2024 3:32pm
From May 30th 2024: "The Company plans to resubmit the pre-BTD submission to the FDA in 2Q2024/3Q2024 for FDA review of these clarifications. Once the pre-BTD submission has been accepted by the FDA, the Company will compile a BTD submission for review by the FDA in support of the grant of a BTD approval." In trying to connect the invisible ink dots: This stated timeline means they have ...more  
Comment by N0taP00p on Jul 05, 2024 4:21pm
@Plantrader: Thank you. Probably a more realistic timeline. Let's hope they are able to submit the pre-BTD on time and get the money they need for Q4. I am assuming we will get an update in the Q2 report sometime in July or August, unless we get an NR specific to the submission before then. 
Comment by Legit62 on Jul 05, 2024 5:11pm
Plantrader thats right to the point, lets not beat our selves up and lets  plan on BTD by end of 1st half of 25 to be safe ,unless for some miraculous happening we get bought out
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.TLT



Investor Presentation

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 75 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

FACT SHEET

View the Presentation

The Watchlist

The Watchlist
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 72 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

Facebook

Contact Us

Address:
41 Hollinger Road
Toronto, ON M4B 3G4
Canada

Toll Free:
1-866-THE-LASE (843-5273)
Local Phone:
416-699-LASE (5273)

Email:
info@theralase.com

Fax:
416-699-5250